Earnings ·
Vericel Corporation reported second quarter 2026 financial results for the period ended June 30, 2026
VCELVericel Corp
Vericel Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Total net revenue increased 22% to $77.5 million, driven by a 23% rise in MACI revenue to $65.5 million and a 22% increase in Burn Care revenue to $12.0 million. The company achieved gross margins of 73%, net income of $2.2 million ($0.04 per diluted share), and free cash flow of $14.3 million. Vericel raised its full-year 2026 total revenue guidance to $330–$340 million from the previous range of $326–$336 million. Additionally, the Board authorized a new $200 million share repurchase program. The company operates in the advanced cell therapy and biologic markets, providing treatments for sports medicine injuries and severe burn care.